Peter Blume-Jensen - 14 Feb 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
14 Feb 2024
Net transactions value
-$142,327
Form type
4
Filing time
16 Feb 2024, 17:06:48 UTC
Previous filing
16 Nov 2023
Next filing
27 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $142,327 -41,861 -1.6% $3.40 2,616,812 14 Feb 2024 Direct F1
holding ACRV Common Stock 318,226 14 Feb 2024 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by co-founder and EVP, Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.